PRAX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$638.68median target· current $368.03 (+73.5%)19 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-12.970.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$10.50BLarge cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 7.83
- P/S (TTM)
- 953.14
- EV/EBITDA
- -6.86
Profitability & growth
- ROE (TTM)
- -38.9%
- Operating margin
- 0.0%
- Revenue growth YoY
- 1349.0%
- Dividend yield
- —
- Beta
- 2.78
Last earnings
Aug 3, 2026 · Estimate $-3.60 · Reported $-2.87
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Praxis Precision Medicines Inc
Company profilePraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The company is headquartered in Cambridge, Massachusetts.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 99 HIGH STREET, BOSTON, MA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$10.50B
Shares outstanding$27.9M
52W high$392.70
52W low$37.19
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent